doxorubicin Cancer Research Results

doxoR, doxorubicin: Click to Expand ⟱
Features:
Doxorubicin, (brand name Adriamycin) is a chemotherapy medication used to treat breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. Often used together with other chemotherapy agents. Given by injection into a vein.
Doxorubicin is an anthracycline chemotherapy whose core anticancer activity is driven by DNA intercalation and topoisomerase II poisoning (DNA double-strand break stress), with additional contributions from redox cycling/iron-linked oxidative injury in some contexts. Its major clinical limitations are myelosuppression and cumulative dose–dependent cardiomyopathy, plus severe tissue injury if extravasated (leaks outside the vein).
-Cumulative cardiomyopathy risk is real and dose-dependent; labels note higher risk at higher cumulative doses (often cited around >550 mg/m², with lower limits in higher-risk patients).
-Mechanism split: tumor kill is primarily Topo II + DNA damage, while cardiotoxicity is strongly linked to TOP2β/mitochondrial pathways (redox/iron biology remains discussed, but not the only story).
-Administration hazard: extravasation can cause severe local injury;

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Topoisomerase II poisoning (DNA double-strand break stress) Topo II–DNA cleavage complexes ↑ → DNA breaks ↑ → apoptosis/senescence ↑ (context) Also affects normal proliferating tissues (marrow, mucosa) P, R Core cytotoxic mechanism Primary anticancer mechanism: stabilization of Topo II–DNA cleavage complexes blocks repair and drives lethal DNA damage responses.
2 DNA intercalation → replication/transcription disruption DNA/RNA synthesis ↓; replication stress ↑ Off-target in normal dividing cells P, R Replication/transcription blockade Intercalation contributes to replication fork stress and complements Topo II poisoning.
3 Redox cycling / iron-associated oxidative injury (context-dependent) ROS / oxidative damage ↑ (reported; model-dependent) Oxidative injury risk in sensitive tissues (esp. heart) ↑ P, R, G Stress amplification Often described as semiquinone redox cycling and iron interactions; the relative importance vs Topo II varies by tissue/model.
4 Cardiotoxicity axis (TOP2β + mitochondrial injury; cumulative-dose dependent) — Risk of cardiomyopathy/heart failure ↑ with cumulative exposure R, G Major dose-limiting toxicity Clinically important boxed-warning toxicity; risk increases with cumulative dose (labels cite higher risk above ~550 mg/m²; higher-risk patients often use lower limits).
5 Myelosuppression (bone marrow progenitors) — Neutropenia/anemia/thrombocytopenia risk ↑ R, G Dose-limiting toxicity Expected on-target effect in rapidly dividing marrow cells; infection risk increases when neutrophils are low.
6 p53 / DNA-damage response programs DDR signaling ↑; p53 pathway engagement ↑ (context) DDR activation in normal tissues contributes to toxicity R, G Cell fate commitment Downstream of DNA breaks: checkpoint activation, apoptosis, senescence, or mitotic catastrophe depending on genotype and dose.
7 Immunogenic cell death signals (DAMP exposure; context-dependent) Potential ICD features ↑ (reported in some systems) — G Immune engagement (conditional) Anthracyclines are often discussed as capable of immunogenic cell death in certain settings; not universal across regimens.
8 Extravasation tissue injury (local) — Severe local tissue damage risk if IV leakage occurs P, R Administration hazard Boxed warning emphasizes severe tissue injury with extravasation; requires strict IV administration controls.
9 Secondary malignancy risk (therapy-related AML/MDS; exposure-dependent) — Rare long-term risk signal ↑ — Late toxicity constraint Listed in boxed warnings/labels as a potential late effect, especially with combination regimens.
10 Cardioprotection strategy (dexrazoxane; selected settings) — Cardiotoxicity risk ↓ (when used appropriately) R, G Risk mitigation Dexrazoxane is used to reduce anthracycline cardiotoxicity; mechanistic literature includes TOP2β-linked protection and other hypotheses.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (direct DNA/Topo interactions begin rapidly)
  • R: 30 min–3 hr (acute DNA-damage response + stress signaling)
  • G: >3 hr (gene programs, apoptosis/senescence, phenotype-level outcomes)
Scientific Papers found: Click to Expand⟱
4431- AgNPs,  doxoR,    Oxidative Stress-Induced Silver Nano-Carriers for Chemotherapy
- in-vitro, BC, 4T1 - in-vivo, BC, 4T1 - in-vitro, Nor, 3T3
AntiCan↑, ROS↑, TumVol↓, EPR↑, selectivity↑, ChemoSen↑,
256- AL,  doxoR,    Allicin Overcomes Doxorubicin Resistance of Breast Cancer Cells by Targeting the Nrf2 Pathway
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
NRF2↓, HO-1↓, p‑Akt↓,
301- ALA,  PacT,  doxoR,    Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients
- Human, BC, NA
BNP↓, TNF-α↓, MDA↓, NeuroT↓,
1999- Api,  doxoR,    Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation
- in-vitro, Nor, NRK52E - in-vitro, Nor, MPC5 - in-vitro, BC, 4T1 - in-vivo, NA, NA
neuroP↑, ChemoSen∅, RenoP↑, selectivity↑, chemoP↑, ROS↑, *ROS∅, *antiOx↑, *toxicity↓,
591- Api,  doxoR,    Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines
- in-vitro, AML, Jurkat - in-vitro, AML, THP1
ATP↓, Casp3↑, γH2AX↑,
938- Api,  doxoR,    Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells
- vitro+vivo, HCC, HepG2
LDHA↓, HK2↓,
2586- Api,  doxoR,    Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway
- in-vitro, HCC, Bel-7402
NRF2↓, ChemoSen↑,
4991- ART/DHA,  doxoR,    Dihydroartemisinin alleviates doxorubicin-induced cardiotoxicity and ferroptosis by activating Nrf2 and regulating autophagy
- in-vivo, Nor, H9c2
*cardioP↑, *ROS↓, *Ferroptosis↓, *NRF2↑, Keap1↓,
1363- Ash,  doxoR,    Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer
- in-vitro, Ovarian, A2780S - in-vitro, Ovarian, CaOV3 - in-vivo, NA, NA
ChemoSen↑, ROS↑, DNAdam↑, TumCCA↑, LC3B↑, TumCG↓, cl‑Casp3↑,
5248- Ba,  BA,  doxoR,    Baicalin and Baicalein Enhance Cytotoxicity, Proapoptotic Activity, and Genotoxicity of Doxorubicin and Docetaxel in MCF-7 Breast Cancer Cells
- in-vitro, BC, MCF7 - in-vitro, Nor, HUVECs
toxicity↝, ChemoSen↑, selectivity↑, Apoptosis↑, necrosis↑, MMP↓, DNAdam↑, cl‑PARP↑, MRP1/ABCC1↓, Bcl-2↓, hepatoP↑, cardioP↑, BioAv↝,
1380- BBR,  doxoR,    treatment with ROS scavenger N-acetylcysteine (NAC) and JNK inhibitor SP600125 could partially attenuate apoptosis and DNA damage triggered by DCZ0358.
- in-vivo, Nor, NA
*ROS↓, *MDA↓, *SOD↑, *NRF2↑, *HO-1↑,
6554- BSB,  doxoR,    α-Bisabolol: A Dietary Sesquiterpene that Attenuates Apoptotic and Nonapoptotic Cell Death Pathways by Regulating the Mitochondrial Biogenesis and Endoplasmic Reticulum Stress–Hippo Signaling Axis in Doxorubicin-Induced Acute Cardiotoxicity in Rats
- in-vivo, Nor, NA
*cardioP↑, *chemoP↑, *antiOx↑, *ROS↓, *toxicity↓, *DNAdam↓, *lipid-P↓, *ER Stress↓,
6560- BSB,  doxoR,    Α-Bisabolol, a Component of German Chamomile Tea Attenuates NLRP3 Inflammasome Mediated Pyroptosis, NF-ΚB/MAPK Signaling Activation and Apoptosis by Invoking NRF2 Mediated Antioxidant Defense Systems in Doxorubicin-Induced Liver Injury in Rats
- in-vivo, Nor, NA
*lipid-P↓, *antiOx↑, *Apoptosis↓, *Inflam↓,
2591- CHr,  doxoR,    Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway
- in-vitro, HCC, Bel-7402
NRF2↓, ChemoSen↑, HO-1↓,
6165- Cin,  doxoR,    Cinnamaldehyde potentiates cytotoxic and apoptogenic effects of doxorubicin in prostate cancer cell line
- in-vitro, Pca, PC3
ChemoSen↑, ROS↑, Casp3↑, Casp7↑,
4763- CoQ10,  Chemo,  doxoR,    Effect of Coenzyme Q10 on Doxorubicin Cytotoxicity in Breast Cancer Cell Cultures
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549
ChemoSen∅, antiNeop∅, *cardioP↑, Dose↝, selectivity↑, TumCG∅, TumCG∅, Apoptosis∅,
6152- CoQ10,  doxoR,    Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment
- Trial, BC, NA
eff↝, CardioT↝, ROS↝, ROS↝, ROS↓,
6532- CRV,  doxoR,    R-(-)-carvone Attenuated Doxorubicin Induced Cardiotoxicity In Vivo and Potentiated Its Anticancer Toxicity In Vitro
- in-vivo, BC, MCF7 - in-vivo, Nor, H9c2
tumCV↓, ChemoSen↑, cardioP↑, *Catalase↑,
6759- DHA,  doxoR,    Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7
ChemoSen↑, i-MDA↑, lipid-P↑, ROS↑,
6603- Ech,  doxoR,    The effect of Echinacea purpurea on the pharmacokinetics of docetaxel
- Trial, Var, NA
other∅, other↝, Imm↑, CYP3A4⇅, other↑,
8591- FS,  doxoR,  carbop,    Flaxseed Lignans Enhance the Cytotoxicity of Chemotherapeutic Agents against Breast Cancer Cell Lines MDA-MB-231 and SKBR3
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, SkBr3
ChemoSen?, Synergy↑, chemoP↑,
8600- FSO,  doxoR,    Combining doxorubicin with a phenolic extract from flaxseed oil: Evaluation of the effect on two breast cancer cell lines
- in-vitro, BC, MCF7
TumCCA↑, ROS↑, Dose↝, ChemoSen↑, MMP↓, Casp3↑,
1972- GamB,  doxoR,    Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression
- in-vitro, BC, NA
ChemoSen↑, P-gp/ABCB1↓, ROS↑, survivin↓, p38↑,
1965- GamB,  doxoR,    Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis
- in-vitro, Ovarian, SKOV3
Synergy↑, AntiCan↑, ROS↑, ChemoSen↑,
2889- HNK,  doxoR,    Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice
- in-vivo, Nor, NA
*SIRT3↑, chemoP↑, *cardioP↑, mtDam↑, ROS↑, *ROS↓, *MMP↑,
2893- HNK,  doxoR,    Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts
- in-vivo, Nor, NA
*mitResp↑, *PPARγ↑, *cardioP↑, *SIRT3↑, *ROS↓, *GSH↑, *SOD2↑,
2901- HNK,  doxoR,    Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts
- in-vivo, Nor, NA
*mitResp↑, *PPARγ↑, *Inflam↓, *ROS↓, *cardioP↑, *SOD2↑, *LDH↓,
5051- HPT,  doxoR,    Hyperthermia Enhances Doxorubicin Therapeutic Efficacy against A375 and MNT-1 Melanoma Cells
- in-vitro, Melanoma, A375
tumCV↓, TumCCA↑, ROS↑, Synergy↑,
7562- HYP,  doxoR,    Hyperoside Inhibits Doxorubicin-Induced Ferroptosis in Cardiomyocytes via the Nrf2/GPX4 Pathway
- in-vivo, Nor, NA
*ROS↓, *Ferroptosis↓, *Apoptosis↓, *cardioP↑, *MDA↓, *SOD↑, *GPx↑, *i-Iron↓, *4-HNE↓, *GSH↑, *Ferritin↑, *ACSL4↓, *NRF2↑, *GPx4↑,
7680- iod,  doxoR,    Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection
- vitro+vivo, BC, NA
antiNeop↑, antiOx↑, Dose↝, TumVol↓, PCNA↓, Weight↑, cardioP↑, ChemoSen↑,
8034- IVM,  doxoR,    Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation
- in-vitro, Oral, NA
tumCV↓, selectivity↑, TumCCA↑, Apoptosis↓, BAX↑, Casp3↑, P53↑, Bcl-2↓, Ki-67↓, IL6↓, ROS↑, mtDam↑,
8050- IVM,  doxoR,    Repurposing Ivermectin to augment chemotherapy's efficacy in osteosarcoma
- in-vitro, OS, NA
ChemoSen↑, TumCG↑, TumCMig↓, Apoptosis↑,
8003- JG,  doxoR,    A juglone derivative that disrupts mitochondrial redox metabolism, inhibiting the breast fibroblast-cancer cell pro-migratory signaling induced by doxorubicin
- in-vitro, BC, NA
TumCP↓, TumCCA↑, mt-NADH↑, mt-OCR↑, mt-SOD2↑,
9072- L-THE,  doxoR,    Protective effects of L-theanine against doxorubicin-induced nephrotoxicity in rats
- in-vivo, Nor, NA
*Dose↝, *GSSG↓, *GGT/CD224↓, *NF-kB↓, *GSH↑, *GPx↑, *GSR↑, *GSTA1↑, *chemoP↑,
9063- L-THE,  doxoR,    L-Theanine Ameliorates Doxorubicin-Induced Ovarian Toxicity by Reducing Endoplasmic Reticulum Stress
- in-vivo, Nor, NA
*Dose↝, *ROS↓, *Inflam↓, *Apoptosis↓, *eff↑, *chemoP↑, *ER Stress↓,
8190- LGE,  doxoR,    Cymbopogon citratus and Citral Overcome Doxorubicin Resistance in Cancer Cells via Modulating the Drug's Metabolism, Toxicity, and Multidrug Transporters
- in-vitro, BC, MCF7 - in-vitro, Liver, HepG2 - in-vitro, Ovarian, SKOV3
ChemoSen↑, CYP3A4↓, PXR, NR1I2↓, GSTA1↓, MDR1↓, MRP1/ABCC1↓, ABCG2↓,
8323- LIN,  doxoR,    Efficacy of Combination Therapy with Linalool and Doxorubicin Encapsulated by Liposomes as a Two-in-One Hybrid Carrier System for Epithelial Ovarian Carcinoma
- vitro+vivo, Ovarian, NA
ChemoSen↑, TumCG↓, Ki-67↓, CD31/PECAM-1↓, Casp3↑, *toxicity↓, chemoP↑, *BioAv↓, EPR↑,
8322- LIN,  doxoR,    Effect of linalool as a component of Humulus lupulus on doxorubicin-induced antitumor activity
- vitro+vivo, Var, NA
ChemoSen↑, TumW↓, Na+↝,
8321- LIN,  doxoR,    Linalool, a plant-derived monoterpene alcohol, reverses doxorubicin resistance in human breast adenocarcinoma cells
- in-vitro, BC, MCF7
ChemoSen↑, EPR↑, Bcl-xL↓, P-gp/ABCB1↓, TumCCA⇅, tumCV↓, Apoptosis↑,
986- LT,  doxoR,    Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells
- in-vitro, BC, 4T1 - in-vitro, BC, MCF7
SOD↓, Catalase↓, Glycolysis↓,
2534- M-Blu,  doxoR,  PDT,    Methylene Blue-Mediated Photodynamic Therapy in Combination With Doxorubicin: A Novel Approach in the Treatment of HT-29 Colon Cancer Cells
- in-vitro, CRC, HT-29
LDH↑, ROS↑,
8484- MF,  doxoR,    Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
ChemoSen↑, Dose↝, eff↑, CDK1?, p‑H3↓, survivin↓, PLK1↓,
8485- MF,  doxoR,    Static magnetic field promotes the doxorubicin toxicity effects on osteosarcoma cells
- in-vitro, OS, G292
tumCV↓, Dose↝, Apoptosis↑, ROS↑, i-Iron↓, *Ca+2↓, *Iron↑, *chemoP↑, ROS↓, ChemoSen↑, selectivity↑,
508- MF,  doxoR,    Synergistic cytotoxic effects of an extremely low-frequency electromagnetic field with doxorubicin on MCF-7 cell line
- in-vitro, BC, MCF7
ROS↑, Apoptosis↑, TumCCA↑,
506- MF,  doxoR,    Pulsed Electromagnetic Field Stimulation Promotes Anti-cell Proliferative Activity in Doxorubicin-treated Mouse Osteosarcoma Cells
- in-vitro, OS, LM8
TumCP↓, p‑CHK1↓, Ca+2↑, Casp3↓, Casp7↓, p‑BAD↓, ChemoSen↑,
4354- MF,  doxoR,    Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
- in-vivo, BC, MDA-MB-231 - in-vivo, BC, MCF7
selectivity↑, Apoptosis↑, TumCI↓, tumCV↓, TumVol↓, eff↓, ChemoSen↑, ROS↑, Ca+2↑, TumCMig↓,
4425- MF,  doxoR,    Brief Magnetic Field Exposure Stimulates Doxorubicin Uptake into Breast Cancer Cells in Association with TRPC1 Expression: A Precision Oncology Methodology to Enhance Chemotherapeutic Outcome
- in-vitro, BC, 4T1 - in-vitro, BC, MCF7
ChemoSen↑, TRPC1↑, Dose↓, selectivity↑,
8479- MFrot,  doxoR,    Dual-targeting by rotating magnetic field-driven superparamagnetic bionic nanorobots for enhanced triple-negative breast cancer therapy
- vitro+vivo, BC, 4T1
Dose?, EPR↑, BioEnh↑, GSH↓, GPx4↓, Iron↑, ROS↑, lipid-P↑, Ferroptosis↑, TumVol↓, Fenton↑,
8619- MO,  doxoR,    Melissa officinalis Protects against Doxorubicin-Induced Cardiotoxicity in Rats and Potentiates Its Anticancer Activity on MCF-7 Cells
- vitro+vivo, BC, MCF7
*Dose↝, *cardioP↑, *ROS↓, *lipid-P↓, *antiOx↑, *Inflam↓, *NF-kB↓, *TNF-α↓, *COX2/PTGS2↓, *MPO↓, ChemoSen↑, *Dose↝, *AST↓, *CK/CK-MB↓, *SOD↑, Synergy↑, MDA↑, NO↑, GSH↓, ROS↑,
8867- MOR,  doxoR,    Morin Sensitizes MDA-MB-231 Triple-Negative Breast Cancer Cells to Doxorubicin Cytotoxicity by Suppressing FOXM1 and Attenuating EGFR/STAT3 Signaling Pathways
- in-vitro, BC, MDA-MB-231
ChemoSen↑, EPR↑, DNAdam↑, γH2AX↑, p‑EGFR↓, p‑STAT3↓, TumCCA↑, P21↑, cycD1/CCND1↓, FOXM1↓, tumCV↓, *p38↑,

Showing Research Papers: 1 to 50 of 68
Page 1 of 2 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 68

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↓, 1,   Catalase↑, 1,   Fenton↑, 1,   GPx4↓, 1,   GSH↓, 2,   GSH↑, 1,   HO-1↓, 2,   Iron↑, 1,   i-Iron↓, 1,   Keap1↓, 1,   lipid-P↑, 2,   MDA↓, 2,   MDA↑, 1,   i-MDA↑, 1,   mt-NADH↑, 1,   NRF2↓, 3,   NRF2∅, 1,   ROS↓, 3,   ROS↑, 22,   ROS↝, 3,   SOD↓, 1,   SOD↑, 1,   mt-SOD2↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↑, 2,   mt-OCR↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

p‑AMPK↑, 1,   ATP↓, 1,   Glycolysis↓, 1,   p‑GSK‐3β↓, 1,   HK2↓, 1,   LDHA↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   Apoptosis↑, 10,   Apoptosis∅, 1,   p‑BAD↓, 1,   BAX↓, 1,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Bcl-2↑, 1,   Bcl-xL↓, 2,   Casp↑, 1,   Casp3↓, 1,   Casp3↑, 9,   cl‑Casp3↑, 1,   Casp7↓, 1,   Casp7↑, 1,   Casp9↑, 2,   Ferroptosis↑, 1,   necrosis↑, 2,   p38↑, 1,   survivin↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   p‑Akt↓, 4,   cMET↓, 1,   p‑EGFR↓, 1,   mTOR↓, 2,   p‑mTOR↓, 1,   PI3K↓, 2,   PI3K/Akt↓, 1,   PTEN↓, 1,   PTEN↑, 1,   p‑STAT3↓, 1,   p‑STK11/LKB1↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

DNMTs↓, 1,   FOXM1↓, 1,   p‑H3↓, 1,   HDAC↓, 1,   other↑, 1,   other↝, 1,   other∅, 1,   tumCV↓, 10,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1/ATG6↑, 1,   LC3A↑, 1,   LC3B↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   DNAdam↑, 5,   DNArepair↓, 1,   P53↑, 2,   PARP↓, 1,   PARP↝, 1,   cl‑PARP↑, 3,   PCNA↓, 1,   γH2AX↑, 2,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1?, 1,   CDK4↓, 1,   p‑CHK1↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 2,   E2Fs↓, 1,   Ki-67↓, 3,   P21↑, 2,   PLK1↓, 1,   TumCCA↑, 12,   TumCCA⇅, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CD133↓, 1,   CSCs↓, 1,   Ki-67↓, 3,   TumCG↓, 3,   TumCG↑, 1,   TumCG∅, 2,   TumCP↓, 2,  

Migration(tgid=13) ⓘ

Ca+2↑, 2,   Na+↝, 1,   NeuroT↓, 1,   TumCI↓, 1,   TumCMig↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

CD31/PECAM-1↓, 1,   Hif1a↓, 1,   NO↑, 1,  

Barriers & Transport(tgid=15) ⓘ

EPR↑, 5,   MMP↓, 5,   Na+↝, 1,   TRPC1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   Imm↑, 2,   TNF-α↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

pH↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

BNP↓, 1,   ER-α36↓, 1,   PXR, NR1I2↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioAv↝, 1,   BioEnh↑, 7,   ChemoSen?, 1,   ChemoSen↑, 36,   ChemoSen∅, 2,   CYP3A4↓, 1,   CYP3A4⇅, 1,   Dose?, 1,   Dose↓, 1,   Dose↝, 6,   eff↓, 3,   eff↑, 4,   eff↝, 1,   GSTA1↓, 1,   MDR1↓, 1,   MRP1/ABCC1↓, 2,   P-gp/ABCB1↓, 3,   RadioS↑, 1,   selectivity?, 1,   selectivity↑, 9,   Synergy↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

p‑EGFR↓, 1,   FOXM1↓, 1,   IL6↓, 1,   LDH↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   antiNeop↑, 1,   antiNeop∅, 1,   cardioP↑, 6,   CardioT↓, 1,   CardioT↝, 1,   chemoP↑, 6,   hepatoP↑, 2,   neuroP↑, 1,   OS↑, 3,   Remission↑, 1,   RenoP↑, 1,   toxicity↝, 1,   TumVol↓, 9,   TumW↓, 1,   Weight↑, 1,  
Total Targets: 171

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

4-HNE↓, 1,   antiOx↑, 5,   Catalase↑, 1,   GPx↑, 2,   GPx4↑, 2,   GSH↑, 5,   GSR↑, 1,   GSSG↓, 1,   HO-1↑, 2,   Iron↑, 1,   i-Iron↓, 1,   lipid-P↓, 3,   MDA↓, 2,   MPO↓, 1,   NOX4↓, 1,   NQO1↑, 1,   NRF2↑, 8,   ROS↓, 13,   ROS∅, 1,   SOD↑, 4,   SOD2↑, 2,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↑, 1,   FTH1↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mitResp↑, 2,   SIRT3↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 3,   Ferroptosis↓, 2,   p38↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Mst1↓, 1,   p‑mTOR↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↓, 2,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↓, 1,   TGF-β↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↑, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   Inflam↓, 5,   NF-kB↓, 2,   NLRP3↓, 1,   TNF-α↓, 2,  

Cellular Microenvironment(tgid=17) ⓘ

GGT/CD224↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PPARγ↑, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioEnh↑, 1,   Dose↝, 4,   eff↓, 2,   eff↑, 1,   GSTA1↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AST↓, 1,   CK/CK-MB↓, 1,   Ferritin↑, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 11,   CardioT↓, 1,   chemoP↑, 4,   toxicity↓, 3,  
Total Targets: 58

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:179  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page